Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Perphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 8/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 6/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 6/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 6/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 6/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | HRH1 | P35367 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perphenazine SCHEMBL29385591 | 1.00 | MAPT (1.00) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL29461866 | 1.00 | MAPT (1.00) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL42125 | 1.00 | MAPT (1.00) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL140891 | 0.99 | MAPT (0.98) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL145754 | 0.99 | MAPT (0.98) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL29846305 | 0.99 | MAPT (0.98) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL5307579 | 0.96 | MAPT (0.91) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL28086447 | 0.96 | MAPT (0.91) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL28456705 | 0.94 | MAPT (0.88) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL8014634 | 0.94 | MAPT (0.88) | MAPTLMNAMAPK1CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137853-A1 | METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-0778773-A1 | METHODS FOR TREATING AND/OR PREVENTING ALZHEIMER'S DISEASE USING PHENOTHIAZINES AND/OR THIOXANTHENES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1997-06-18 | — | — | EP | disclosed |
| WO-1996004915-A1 | METHODS FOR TREATING AND/OR PREVENTING ALZHEIMER'S DISEASE USING PHENOTHIAZINES AND/OR THIOXANTHENES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137853-A1 | METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE | SLC6A4, SLC1A2, SLC6A2 | DRD2 172/4885MAPT 1551/4885LMNA 3620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.